MX2021015311A - Formulas parenterales de lisofosfatidilcolina tales como lpc-dha, lpc-epa y sus usos en terapia. - Google Patents

Formulas parenterales de lisofosfatidilcolina tales como lpc-dha, lpc-epa y sus usos en terapia.

Info

Publication number
MX2021015311A
MX2021015311A MX2021015311A MX2021015311A MX2021015311A MX 2021015311 A MX2021015311 A MX 2021015311A MX 2021015311 A MX2021015311 A MX 2021015311A MX 2021015311 A MX2021015311 A MX 2021015311A MX 2021015311 A MX2021015311 A MX 2021015311A
Authority
MX
Mexico
Prior art keywords
lpc
therapy
formulations
lysophosphatidylcholine
dha
Prior art date
Application number
MX2021015311A
Other languages
English (en)
Inventor
Nils Hoem
Finn Myhren
Petter- Arnt Hals
Lotte Skolem
Storsve Andreas Berg
Armend Gazmeno Håti
Original Assignee
Aker Biomarine Antarctic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aker Biomarine Antarctic As filed Critical Aker Biomarine Antarctic As
Publication of MX2021015311A publication Critical patent/MX2021015311A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a formulaciones farmacéuticas de fosfolípidos y, en particular, a formulaciones farmacéuticas que se administran por vía intravascular, tal como por vía intravenosa. En particular, la presente invención proporciona composiciones farmacéuticas para la administración intravascular que comprenden compuestos derivados de fosfatidilcolina que portan un ácido graso omega-3 para su uso en profilaxis o terapia.
MX2021015311A 2019-06-20 2020-06-21 Formulas parenterales de lisofosfatidilcolina tales como lpc-dha, lpc-epa y sus usos en terapia. MX2021015311A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962864073P 2019-06-20 2019-06-20
PCT/EP2020/067263 WO2020254675A1 (en) 2019-06-20 2020-06-21 Parenteral lysophosphatidylcholine formulations such as lpc-dha, lpc-epa and their use in therapy

Publications (1)

Publication Number Publication Date
MX2021015311A true MX2021015311A (es) 2022-02-21

Family

ID=71138732

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015311A MX2021015311A (es) 2019-06-20 2020-06-21 Formulas parenterales de lisofosfatidilcolina tales como lpc-dha, lpc-epa y sus usos en terapia.

Country Status (11)

Country Link
US (1) US20230038627A1 (es)
EP (1) EP3986418A1 (es)
JP (1) JP2022537366A (es)
KR (1) KR20220049506A (es)
CN (1) CN114286680A (es)
AU (1) AU2020298105A1 (es)
BR (1) BR112021025477A2 (es)
CA (1) CA3143586A1 (es)
IL (1) IL289096A (es)
MX (1) MX2021015311A (es)
WO (1) WO2020254675A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4125855A2 (en) * 2020-03-31 2023-02-08 Aker Biomarine Antarctic As Krill oil composition enriched in lpc-dha and lpc-epa
WO2022101678A2 (en) 2020-11-15 2022-05-19 Aker Biomarine Antarctic As Lysophospholipid formulations
WO2022125684A1 (en) * 2020-12-08 2022-06-16 Orochem Technologies Inc. Process for purifying lpc-dha and/or lpc-epa using a chromatographic stationary phase and compositions thereof
WO2023081388A1 (en) * 2021-11-05 2023-05-11 The Feinstein Institutes For Medical Research Lysophosphatidylcholine combinations as a therapy to treat cardiac arrest
CN115531399A (zh) * 2022-09-15 2022-12-30 首都医科大学 溶血磷脂酰胆碱在治疗阿尔茨海默病中的应用
US12023359B2 (en) 2022-11-01 2024-07-02 Aker Biomarine Human Ingredients As Phospholipid compositions for delivery of therapeutic compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008068413A2 (fr) 2006-11-14 2008-06-12 INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE LYON (INSA de Lyon) Procede de preparation d'acetyl, docosahexaenoyl-glycérophosphocholine, et son utilisation pour l'apport d'acides gras polyinsatures
EP2488190B1 (en) 2009-10-13 2017-09-20 DSM IP Assets B.V. Reducing the risk of pathological effects of traumatic brain injury
PT2493478T (pt) * 2009-10-29 2018-04-03 Acasti Pharma Inc Composições terapêuticas concentradas de fosfolípidos
KR101951933B1 (ko) 2013-03-12 2019-02-25 주식회사 아리바이오 라이소포스파티딜콜린 또는 이의 유도체를 포함하는 지질나노물질 및 이의 제조방법
CN113908296A (zh) * 2013-09-26 2022-01-11 新加坡国立大学 利用溶血磷脂酰胆碱支架的组合物和方法
FR3038606B1 (fr) * 2015-07-06 2018-10-05 Institut National Des Sciences Appliquees De Lyon Glycerophosphocholines, pour leur utilisation dans le traitement d'une inflammation intestinale ou d'un cancer intestinal
FR3063645B1 (fr) 2017-03-08 2021-06-11 Lipther Acefapc pour le traitement des maladies acetylcholine dependantes
US10555957B2 (en) * 2017-05-10 2020-02-11 The Board Of Trustees Of The University Of Illinois Methods and compositions for enriching DHA levels in the brain
JP2021508343A (ja) 2017-12-21 2021-03-04 エーケル バイオマリーン アンタークティク エーエス リゾホスファチジルコリン組成物

Also Published As

Publication number Publication date
JP2022537366A (ja) 2022-08-25
AU2020298105A1 (en) 2022-01-20
CA3143586A1 (en) 2020-12-24
WO2020254675A1 (en) 2020-12-24
BR112021025477A2 (pt) 2022-03-03
IL289096A (en) 2022-02-01
US20230038627A1 (en) 2023-02-09
KR20220049506A (ko) 2022-04-21
EP3986418A1 (en) 2022-04-27
CN114286680A (zh) 2022-04-05

Similar Documents

Publication Publication Date Title
MX2021015311A (es) Formulas parenterales de lisofosfatidilcolina tales como lpc-dha, lpc-epa y sus usos en terapia.
AU2016343803A8 (en) Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
PH12020550341A1 (en) Niraparib formulations
BR112018010024A2 (pt) compostos e composições úteis no tratamento de distúrbios relacionados a ntrk
NZ742220A (en) Pharmaceutical compositions comprising meloxicam
MX2018015709A (es) Derivados de azabencimidazol como inhibidores de pi3k beta.
PH12017502181A1 (en) Nutritional compositions containing an elevated level of inositol and uses thereof
AR105808A1 (es) Compuestos de amida para el tratamiento de trastornos médicos
PH12016501519B1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX2014002362A (es) Formulaciones y formas de dosificacion de fosfolipidos oxidados.
PH12018500036A1 (en) Nutritional compositions containing phosphatidylethanolamine, sphingomyelin and docosahexaenoic acid
MX2020002238A (es) Composiciones de acidos grasos y ester de acido graso autoformadores de micelas y su uso en el tratamiento de patologias.
SG10201907291QA (en) Monomethylfumarate prodrug compositions
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
WO2020141828A3 (en) Anticancer compositions comprising immune checkpoint inhibitors
MX2022013450A (es) Formulaciones farmaceuticas.
MX2017005163A (es) Composiciones de liberación prolongada de onapristona y métodos.
MX2016005900A (es) Profarmaco mutuo que comprende acidos grasos de cadena corta y zebularina o 1'-ciano-citarabina para tratamiento del cancer.
JP2016516773A5 (es)
BR112015012497A8 (pt) combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
EA201300947A1 (ru) Композиция для повышения устойчивости суставов и/или позной устойчивости
PH12015502727A1 (en) Methods and compositions for enhancing cognitive performance
WO2017021974A3 (en) NOVEL SYNERGISTIC COMPOSITION OF LECITHIN AND LYSOLECHINE TO IMPROVE BIOAVAILABILITY AND SOLUBILITY OF HYDROPHOBIC COMPOUNDS AND EXTRACTS